JAK2 and myeloproliferative neoplasm: They are more frequent in post-PV/ET MF, PMF and blast-phase MPN, and coexist with JAK2, MPL and CALR mutations, indicating that these abnormalities could involved in disease clonal evolution or blastic transformation of MPNs [18–20].